VERX Latest News

Vertex Pharmaceuticals: Label Expansions For ALYFTREK And TRIKAFTA Plus Strong Demand

seekingalpha.com — Apr 2, 2026

Vertex Pharmaceuticals (VRTX) remains a "Strong Buy", driven by robust CF franchise growth and successful label expansions for ALYFTREK and TRIKAFTA.

Vertex Announces US FDA Approval for Label Extensions of ALYFTREK® and TRIKAFTA®, Expanding Availability of These Medicines to ~95% of All People With CF in the United States

businesswire.com — Apr 1, 2026

BOSTON--(BUSINESS WIRE)--Vertex Pharmaceuticals Incorporated (Nasdaq: VRTX) today announced the U. S.

VERTEX Shareholders Are Encouraged to Reach Out to Johnson Fistel for More Information About Potentially Recovering Their Losses

globenewswire.com — Mar 25, 2026

SAN DIEGO, March 25, 2026 (GLOBE NEWSWIRE) -- Johnson Fistel, PLLP is investigating potential claims on behalf of investors of Vertex, Inc. (NASDAQ:

Vertex (NASDAQ:VERX) & UiPath (NYSE:PATH) Head to Head Survey

defenseworld.net — Mar 23, 2026

Vertex (NASDAQ: VERX - Get Free Report) and UiPath (NYSE: PATH - Get Free Report) are both mid-cap computer and technology companies, but which is the

Vertex Stock Falls 4.8% in a Month: Buying Opportunity or Red Flag?

zacks.com — Mar 20, 2026

VRTX stock slips nearly 5% as concerns over new drug uptake and pipeline setbacks weigh, even as its dominant CF franchise continues to drive steady g